This study will recruit 20 women who are high risk for prenatal cannabis use for a 12-week program of using the tracker and receiving a Lifestyle Physical Activity program. The primary outcomes will be self reported percent days of cannabis use and physical activity. Secondary outcomes include self -reported measures of depression and anxiety symptoms, adaptive coping, and self-efficacy for cannabis abstinence.
This study will recruit 20 women in an open trial who are high risk for prenatal cannabis use for a 12-week program of using a Fitbit activity tracker and receiving a Lifestyle Physical Activity program. The primary outcomes will be self reported percent days of cannabis use and physical activity. Secondary outcomes include self -reported measures of depression and anxiety symptoms, adaptive coping, and self-efficacy for cannabis abstinence. The investigators will clinically monitor all participants in the study for safety and clinical deterioration, and measure a variety of symptom outcomes over the course of the intervention period during pregnancy, as well as at a postpartum follow-up.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
50
Participants will receive a Fitbit to track activity levels and participate in a 6-session lifestyle physical activity intervention over the course of 12 weeks. The intervention consists of 20-25 minute phone or video-delivered session to: (a) review PA progress and re-evaluate current step-count goals, (b) problem-solve barriers to incorporating PA into their daily lives, (c) address difficulties utilizing the Fitbit, (d) encourage the use of bouts of PA as a coping strategy, and e) engage the participant in brief discussions focused on increasing and maintaining PA.
Participants will receive a Fitbit to track activity levels and participate in 6 brief check-ins to assess any issues with the Fitbit device or app.
Butler Hospital
Providence, Rhode Island, United States
RECRUITINGTimeline Follow-back (TLFB)
Interviewer-administered assessment of use of cannabis, alcohol, tobacco, and other drugs
Time frame: Baseline to 12-week endpoint
Steps/day
objectively-measured
Time frame: Baseline to 12-week endpoint
Activity Minutes/Day
objectively-measured
Time frame: Baseline to 12-week endpoint
The Daily Sessions, Frequency & Quantity of Cannabis Use Inventory - Factor 1
Self-reported cannabis use questionnaire -factor 1: daily sessions
Time frame: Baseline to 12-week endpoint
The Daily Sessions, Frequency & Quantity of Cannabis Use Inventory - Factor 2
Self-reported cannabis use questionnaire - factor 2: frequency
Time frame: Baseline to 12-week endpoint
The Daily Sessions, Frequency & Quantity of Cannabis Use Inventory - Factor 3
Self-reported cannabis use questionnaire - factor 3: age of onset
Time frame: Baseline to 12-week endpoint
The Daily Sessions, Frequency & Quantity of Cannabis Use Inventory - Factor 4
Self-reported cannabis use questionnaire - factor 4: Marijuana quantity
Time frame: Baseline to 12-week endpoint
The Daily Sessions, Frequency & Quantity of Cannabis Use Inventory - Factor 5
Self-reported cannabis use questionnaire - factor 5: Concentrate quantity
Time frame: Baseline to 12-week endpoint
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
The Daily Sessions, Frequency & Quantity of Cannabis Use Inventory - Factor 6
Self-reported cannabis use questionnaire - factor 6: Edibles quantity
Time frame: Baseline to 12-week endpoint
Urine Toxicology Screen
Objective screening for use of cannabis via measurement of THC in urine samples
Time frame: Baseline to 12-week endpoint
International Physical Activity Questionnaire
self-report measure of physical activity including minutes/week spent walking, engaging in moderate physical activity, and engaging in vigorous physical activity
Time frame: Baseline to 12-week endpoint
Brief COPE
Self-report measure of of use of coping strategies; includes 14 2-item scales, each ranging form 2-8. Higher scores indicate increased utilization of a coping strategy.
Time frame: Baseline to 12-week endpoint
Marijuana Self-Efficacy Questionnaire
Self-report measure of efficacy for cannabis abstinence; Scores range from 0-100, with higher scores indicating greater use of strategies to reduce marijuana consumption.
Time frame: Baseline to 12-week endpoint
Edinburgh Postnatal Depression Screen
Self-report measure of depression severity; scores range from 0-30, with higher scores indicating higher depression
Time frame: Baseline to 12-week endpoint
Generalized Anxiety Disorder -7
Self-report measure of anxiety severity; scores range from 0-21, with higher scoring indicating more anxiety
Time frame: Baseline to 12-week endpoint